Dr. Ogugua N. Obi, Director of the Sarcoidosis Center of Excellence at ECU, presented the latest update on XTMAB-16 in Sarcoidosis: First-in-Patient Study Results. In this phase 1b/2a MAD study, XTMAB-16 demonstrated a favorable safety and tolerability profile in patients with pulmonary sarcoidosis, without unexpected TNF-inhibitor class effects. Preliminary efficacy signals suggest that XTMAB-16 may facilitate corticosteroid reduction while preserving lung function and improving patient-reported outcomes. These findings support continued clinical development and dose selection for further evaluation.

Sarcoidosis is a chronic, multisystem inflammatory disorder of unknown etiology that is characterized by the formation of granulomas in one or more organs in the body, with key pro-inflammatory cytokine tumor necrosis factor-alpha (TNF) implicated in granuloma formation and disease persistence. Sarcoidosis affects people of all ages but most commonly affects young and middle-aged adults. There are fewer than 200,000 sarcoidosis patients in the US, and no therapies have been developed and approved specifically for the treatment of sarcoidosis to date. Chronic corticosteroid dependence and its associated complications continue to emphasize the unmet need for alternative treatment options for patients living with sarcoidosis.

XTMAB-16 is a chimeric human-murine anti-TNF monoclonal antibody being developed as a biologic product for the treatment of pulmonary sarcoidosis with or without extra pulmonary involvement. Based on its ability to block TNF, XTMAB-16 may disrupt an inflammatory pathway and help slow granuloma formation.

Click Here to See the Full Presentation